Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Procom One, Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The company's current prosecution is limited to 1 distinct examiner and 1 distinct art unit. This concentration indicates that the company is presently focused on a specific technological challenge or a single patent family within the biotechnology field, rather than maintaining a large and diverse set of active applications.
VALENROD, YEVGENY is the busiest examiner for the company, holding the 1 busiest examiner pending office action. Because the portfolio's active workload is managed by 1 distinct examiner, the prosecution strategy must be tailored specifically to this individual's requirements and past actions. The involvement of only 1 distinct art unit means that the company's current interactions with the USPTO are confined to one specific administrative group, which streamlines the focus of their legal representatives. This management of 1 pending office action under a single examiner provides a clear but narrow path toward patent allowance.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VALENROD, YEVGENY | 1 | 72.6% | +25.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17588975 | Low-Dose Doxepin For Treatment Of Sleep Disorders In Elderly Patients | VALENROD, YEVGENY | 97d overdue |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17588975 | Low-Dose Doxepin For Treatment Of Sleep Disorders In Elderly Patients | VALENROD, YEVGENY | 1628 | §103§112DP | Final Rejection | 97d overdue | Pending | Jan 31, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialProcom One, Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Yevgeny Valenrod has the most, with 1 of Procom One, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.